ABL1 is altered in 4.17% of mixed phenotype acute leukemia patients [2].

ABL1 is an inclusion eligibility criterion in 5 clinical trials for mixed phenotype acute leukemia, of which 4 are open and 1 is closed. Of the trials that contain ABL1 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), and 1 is phase 2/phase 3 (1 open) [3].

ABL2 is an inclusion eligibility criterion in 2 clinical trials for mixed phenotype acute leukemia, of which 2 are open and 0 are closed. Of the trials that contain ABL2 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2/phase 3 (1 open) [3].

AFF1 is an inclusion eligibility criterion in 2 clinical trials for mixed phenotype acute leukemia, of which 1 is open and 1 is closed. Of the trials that contain AFF1 status and mixed phenotype acute leukemia as inclusion criteria, 2 are phase 2 (1 open) [3].

ASXL1 is altered in 4.17% of mixed phenotype acute leukemia patients [2].

ASXL1 is an inclusion eligibility criterion in 1 clinical trial for mixed phenotype acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains ASXL1 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

BCR is altered in 3.45% of mixed phenotype acute leukemia patients [2].

BCR is an inclusion eligibility criterion in 5 clinical trials for mixed phenotype acute leukemia, of which 4 are open and 1 is closed. Of the trials that contain BCR status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), and 1 is phase 2/phase 3 (1 open) [3].

CEP72 is an inclusion eligibility criterion in 1 clinical trial for mixed phenotype acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains CEP72 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

CRLF2 is an inclusion eligibility criterion in 2 clinical trials for mixed phenotype acute leukemia, of which 2 are open and 0 are closed. Of the trials that contain CRLF2 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2/phase 3 (1 open) [3].

CSF1R is an inclusion eligibility criterion in 1 clinical trial for mixed phenotype acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

DEK is an inclusion eligibility criterion in 3 clinical trials for mixed phenotype acute leukemia, of which 2 are open and 1 is closed. Of the trials that contain DEK status and mixed phenotype acute leukemia as inclusion criteria, 3 are phase 2 (2 open) [3].

ELL is an inclusion eligibility criterion in 2 clinical trials for mixed phenotype acute leukemia, of which 1 is open and 1 is closed. Of the trials that contain ELL status and mixed phenotype acute leukemia as inclusion criteria, 2 are phase 2 (1 open) [3].

EPOR is an inclusion eligibility criterion in 2 clinical trials for mixed phenotype acute leukemia, of which 2 are open and 0 are closed. Of the trials that contain EPOR status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2/phase 3 (1 open) [3].

FGFR1 is an inclusion eligibility criterion in 2 clinical trials for mixed phenotype acute leukemia, of which 2 are open and 0 are closed. Of the trials that contain FGFR1 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2/phase 3 (1 open) [3].

FGFR2 is an inclusion eligibility criterion in 2 clinical trials for mixed phenotype acute leukemia, of which 2 are open and 0 are closed. Of the trials that contain FGFR2 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2/phase 3 (1 open) [3].

FGFR3 is an inclusion eligibility criterion in 2 clinical trials for mixed phenotype acute leukemia, of which 2 are open and 0 are closed. Of the trials that contain FGFR3 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2/phase 3 (1 open) [3].

FGFR4 is an inclusion eligibility criterion in 2 clinical trials for mixed phenotype acute leukemia, of which 2 are open and 0 are closed. Of the trials that contain FGFR4 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2/phase 3 (1 open) [3].

FLT3 is altered in 6.25% of mixed phenotype acute leukemia patients [2].

FLT3 is an inclusion eligibility criterion in 5 clinical trials for mixed phenotype acute leukemia, of which 4 are open and 1 is closed. Of the trials that contain FLT3 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), and 1 is phase 2/phase 3 (1 open) [3].

IL7R is altered in 3.45% of mixed phenotype acute leukemia patients [2].

IL7R is an inclusion eligibility criterion in 2 clinical trials for mixed phenotype acute leukemia, of which 2 are open and 0 are closed. Of the trials that contain IL7R status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2/phase 3 (1 open) [3].

JAK1 is altered in 3.45% of mixed phenotype acute leukemia patients [2].

JAK1 is an inclusion eligibility criterion in 2 clinical trials for mixed phenotype acute leukemia, of which 2 are open and 0 are closed. Of the trials that contain JAK1 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2/phase 3 (1 open) [3].

JAK2 is altered in 2.08% of mixed phenotype acute leukemia patients [2].

JAK2 is an inclusion eligibility criterion in 2 clinical trials for mixed phenotype acute leukemia, of which 2 are open and 0 are closed. Of the trials that contain JAK2 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2/phase 3 (1 open) [3].

JAK3 is altered in 10.0% of mixed phenotype acute leukemia patients [2].

JAK3 is an inclusion eligibility criterion in 2 clinical trials for mixed phenotype acute leukemia, of which 2 are open and 0 are closed. Of the trials that contain JAK3 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2/phase 3 (1 open) [3].

KMT2A is an inclusion eligibility criterion in 6 clinical trials for mixed phenotype acute leukemia, of which 5 are open and 1 is closed. Of the trials that contain KMT2A status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (3 open) [3].

LYN is an inclusion eligibility criterion in 2 clinical trials for mixed phenotype acute leukemia, of which 2 are open and 0 are closed. Of the trials that contain LYN status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2/phase 3 (1 open) [3].

MDM2 is an inclusion eligibility criterion in 1 clinical trial for mixed phenotype acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains MDM2 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].

MDM4 is an inclusion eligibility criterion in 1 clinical trial for mixed phenotype acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].

MECOM is an inclusion eligibility criterion in 6 clinical trials for mixed phenotype acute leukemia, of which 5 are open and 1 is closed. Of the trials that contain MECOM status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (3 open) [3].

MLF1 is an inclusion eligibility criterion in 4 clinical trials for mixed phenotype acute leukemia, of which 4 are open and 0 are closed. Of the trials that contain MLF1 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].

MLLT1 is an inclusion eligibility criterion in 2 clinical trials for mixed phenotype acute leukemia, of which 1 is open and 1 is closed. Of the trials that contain MLLT1 status and mixed phenotype acute leukemia as inclusion criteria, 2 are phase 2 (1 open) [3].

MLLT10 is an inclusion eligibility criterion in 2 clinical trials for mixed phenotype acute leukemia, of which 1 is open and 1 is closed. Of the trials that contain MLLT10 status and mixed phenotype acute leukemia as inclusion criteria, 2 are phase 2 (1 open) [3].

MLLT3 is an inclusion eligibility criterion in 2 clinical trials for mixed phenotype acute leukemia, of which 1 is open and 1 is closed. Of the trials that contain MLLT3 status and mixed phenotype acute leukemia as inclusion criteria, 2 are phase 2 (1 open) [3].

MLLT4 is an inclusion eligibility criterion in 2 clinical trials for mixed phenotype acute leukemia, of which 1 is open and 1 is closed. Of the trials that contain MLLT4 status and mixed phenotype acute leukemia as inclusion criteria, 2 are phase 2 (1 open) [3].

NPM1 is altered in 4.26% of mixed phenotype acute leukemia patients [2].

NPM1 is an inclusion eligibility criterion in 5 clinical trials for mixed phenotype acute leukemia, of which 5 are open and 0 are closed. Of the trials that contain NPM1 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [3].

NRIP3 is an inclusion eligibility criterion in 2 clinical trials for mixed phenotype acute leukemia, of which 1 is open and 1 is closed. Of the trials that contain NRIP3 status and mixed phenotype acute leukemia as inclusion criteria, 2 are phase 2 (1 open) [3].

NTRK1 is an inclusion eligibility criterion in 2 clinical trials for mixed phenotype acute leukemia, of which 2 are open and 0 are closed. Of the trials that contain NTRK1 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2/phase 3 (1 open) [3].

NTRK2 is an inclusion eligibility criterion in 2 clinical trials for mixed phenotype acute leukemia, of which 2 are open and 0 are closed. Of the trials that contain NTRK2 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2/phase 3 (1 open) [3].

NTRK3 is an inclusion eligibility criterion in 2 clinical trials for mixed phenotype acute leukemia, of which 2 are open and 0 are closed. Of the trials that contain NTRK3 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2/phase 3 (1 open) [3].

NUP214 is an inclusion eligibility criterion in 3 clinical trials for mixed phenotype acute leukemia, of which 2 are open and 1 is closed. Of the trials that contain NUP214 status and mixed phenotype acute leukemia as inclusion criteria, 3 are phase 2 (2 open) [3].

PDGFRA is an inclusion eligibility criterion in 2 clinical trials for mixed phenotype acute leukemia, of which 2 are open and 0 are closed. Of the trials that contain PDGFRA status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2/phase 3 (1 open) [3].

PDGFRB is an inclusion eligibility criterion in 2 clinical trials for mixed phenotype acute leukemia, of which 2 are open and 0 are closed. Of the trials that contain PDGFRB status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2/phase 3 (1 open) [3].

PPM1D is an inclusion eligibility criterion in 1 clinical trial for mixed phenotype acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains PPM1D status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].

RPN1 is an inclusion eligibility criterion in 6 clinical trials for mixed phenotype acute leukemia, of which 5 are open and 1 is closed. Of the trials that contain RPN1 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (3 open) [3].

RUNX1 is altered in 18.75% of mixed phenotype acute leukemia patients [2].

RUNX1 is an inclusion eligibility criterion in 1 clinical trial for mixed phenotype acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

SH2B3 is an inclusion eligibility criterion in 2 clinical trials for mixed phenotype acute leukemia, of which 2 are open and 0 are closed. Of the trials that contain SH2B3 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2/phase 3 (1 open) [3].

SMARCA4 is an inclusion eligibility criterion in 1 clinical trial for mixed phenotype acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].

SMARCB1 is an inclusion eligibility criterion in 1 clinical trial for mixed phenotype acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].

TET2 is altered in 12.5% of mixed phenotype acute leukemia patients [2].

TET2 is an inclusion eligibility criterion in 1 clinical trial for mixed phenotype acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains TET2 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].

TP53 is altered in 12.5% of mixed phenotype acute leukemia patients [2].

TP53 is an inclusion eligibility criterion in 3 clinical trials for mixed phenotype acute leukemia, of which 2 are open and 1 is closed. Of the trials that contain TP53 status and mixed phenotype acute leukemia as inclusion criteria, 3 are phase 2 (2 open) [3].

TYK2 is an inclusion eligibility criterion in 2 clinical trials for mixed phenotype acute leukemia, of which 2 are open and 0 are closed. Of the trials that contain TYK2 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2/phase 3 (1 open) [3].